Literature DB >> 2537321

Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.

R Picone1, E L Kajtaniak, L S Nielsen, N Behrendt, M R Mastronicola, M V Cubellis, M P Stoppelli, S Pedersen, K Danø, F Blasi.   

Abstract

A specific surface receptor for urokinase plasminogen activator (uPA) recognizes the amino-terminal growth factor-like sequence of uPA, a region independent from and not required for the catalytic activity of this enzyme. The properties of the uPA receptor (uPAR) and the localization and distribution of uPA in tumor cells and tissues suggest that the uPA/uPAR interaction may be important in regulating extracellular proteolysis-dependent processes (e.g., invasion, tissue destruction). Phorbol myristate acetate (PMA), an inducer of U937 cell differentiation to macrophage-like cells, elicits a time- and concentration-dependent increase in the number of uPAR molecules as shown by binding, cross-linking, and immunoprecipitation studies. The effect of PMA is blocked by cycloheximide. Overall, the data indicate that PMA increases the synthesis of uPA. PMA treatment also causes a decrease in the affinity of the uPAR for uPA, thus uncovering another way of regulating the interaction between uPA and uPAR. In addition, the PMA treatment causes a modification of migration of the cross-linked receptor in mono- and bidimensional gel electrophoresis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537321      PMCID: PMC2115427          DOI: 10.1083/jcb.108.2.693

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  58 in total

Review 1.  Human plasminogen activators. Genes and proteins structure.

Authors:  F Blasi; A Riccio; G Sebastio
Journal:  Horiz Biochem Biophys       Date:  1986

2.  Tumor-promoting phorbol esters inhibit binding of epidermal growth factor to cellular receptors.

Authors:  L S Lee; I B Weinstein
Journal:  Science       Date:  1978-10-20       Impact factor: 47.728

3.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.

Authors:  P A Andreasen; L S Nielsen; P Kristensen; J Grøndahl-Hansen; L Skriver; K Danø
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

4.  Patterns of protein synthesis in E. coli: a catalog of the amount of 140 individual proteins at different growth rates.

Authors:  S Pedersen; P L Bloch; S Reeh; F C Neidhardt
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Surface characteristics of the U-937 human histiocytic lymphoma cell line: specific changes during inducible morphologic and functional differentiation in vitro.

Authors:  K Nilsson; K Forsbeck; M Gidlund; C Sundström; T Tötterman; J Sällström; P Venge
Journal:  Haematol Blood Transfus       Date:  1981

7.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

8.  Tumor-promoting phorbol diesters mediate phosphorylation of the epidermal growth factor receptor.

Authors:  R J Davis; M P Czech
Journal:  J Biol Chem       Date:  1984-07-10       Impact factor: 5.157

9.  Inhibition of insulin receptor binding by phorbol esters.

Authors:  P Thomopoulos; U Testa; M F Gourdin; C Hervy; M Titeux; W Vainchenker
Journal:  Eur J Biochem       Date:  1982-12-15

10.  Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface.

Authors:  J Huarte; D Belin; D Bosco; A P Sappino; J D Vassalli
Journal:  J Cell Biol       Date:  1987-05       Impact factor: 10.539

View more
  37 in total

1.  Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.

Authors:  R P Czekay; T A Kuemmel; R A Orlando; M G Farquhar
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

4.  Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.

Authors:  Anne M Brooks; Mary Ellen Bates; Rose F Vrtis; Nizar N Jarjour; Paul J Bertics; Julie B Sedgwick
Journal:  Am J Respir Cell Mol Biol       Date:  2006-05-25       Impact factor: 6.914

5.  Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells.

Authors:  S Shetty; A Kumar; S Idell
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

6.  The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes.

Authors:  R G Sitrin; R F Todd; E Albrecht; M R Gyetko
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

7.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.

Authors:  A R Nusrat; H A Chapman
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

10.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.